Key result
Glimepiride (1-8 mg/day) is as effective as glyburide and glipizide in lowering glucose levels, but is associated with a reduced likelihood of hypoglycemia.
Why the study?
Does glimepiride improve glycemic control and reduce hypoglycemia compared to other sulfonylureas in patients with type 2 diabetes mellitus?
Population
Patients with type 2 diabetes mellitus
Comparison
Glimepiride (1-8 mg/day) vs Other sulfonylureas (glyburide, glipizide)
Design
Review
Authors
Loading...
May support glimepiride preference in T2DM to lower hypoglycemia risk; leaves open need for RCTs on long-term outcomes.
Does glimepiride improve glycemic control and reduce hypoglycemia compared to other sulfonylureas in patients with type 2 diabetes mellitus?
Glimepiride is an effective and safe first-line therapy for type 2 diabetes, offering comparable glycemic control to older sulfonylureas but with a lower risk of hypoglycemia and potential preservation of cardioprotective responses.
Mary T. Korytkowski (2004) conducted a review in Type 2 diabetes mellitus. Glimepiride vs. Glyburide and glipizide was evaluated. Glimepiride (1-8 mg/day) is as effective as glyburide and glipizide in lowering glucose levels, but is associated with a reduced likelihood of hypoglycemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: